TGFβ signaling and congenital heart disease: Insights from mouse studies

Birth Defects Research Part A - Clinical and Molecular Teratology

Volumn 91, Issue 6, 2011, Pages 423-434

  Arthur, Helen M ^a   Bamforth, Simon D ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Betaglycan; Cushion mesenchyme; Endoglin; Epithelial to mesenchymal transition; Loeys Dietz syndrome; TGF receptors

Indexed keywords

ELASTIN; ENDOGLIN; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 3; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; TRANSFORMING GROWTH FACTOR BETA3;

ANIMAL GENETICS; ANIMAL MODEL; AORTA ARCH; CELL DIFFERENTIATION; CONGENITAL HEART DISEASE; CORONARY ARTERY; EMBRYO DEVELOPMENT; ENDOCARDIAL CUSHION; EPITHELIAL MESENCHYMAL TRANSITION; GENE DELETION; GENE MUTATION; GREAT BLOOD VESSEL; HEART DEVELOPMENT; HEART MUSCLE CELL; HUMAN; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; KNOCKOUT MOUSE; LOEYS DIETZ SYNDROME; MESENCHYME CELL; MOLECULAR MODEL; MORPHOGENESIS; MUTANT; NEURAL CREST CELL; NONHUMAN; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR GENE; REVIEW; SIGNAL TRANSDUCTION; VASCULAR SMOOTH MUSCLE;

ANIMALS; HEART DEFECTS, CONGENITAL; HUMANS; MESODERM; MICE; MUSCLE, SMOOTH, VASCULAR; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA; VENTRICULAR REMODELING;

EID: 79958104536     PISSN: 15420752     EISSN: 15420760     Source Type: Journal    
DOI: 10.1002/bdra.20794     Document Type: Review

References (105)

1. Akhurst RJ, Lehnert SA, Faissner A, et al. 1990. TGF beta in murine morphogenetic processes: the early embryo and cardiogenesis. Development 108: 645-656.
2. Allinson KR, Carvalho RL, van den Brink S, et al. 2007. Generation of a floxed allele of the mouse Endoglin gene. Genesis 45: 391-395.
3. Arthur HM, Ure J, Smith AJ, et al. 2000. Endoglin, an ancillary TGFbeta receptor, is required for extraembryonic angiogenesis and plays a key role in heart development. Dev Biol 217: 42-53.
4. Azhar M, Runyan RB, Gard C, et al. 2009a. Ligand-specific function of transforming growth factor beta in epithelial-mesenchymal transition in heart development. Dev Dyn 238: 431-442.
5. Azhar M, Schultz Jel J, Grupp I, et al. 2003. Transforming growth factor beta in cardiovascular development and function. Cytokine Growth Factor Rev 14: 391-407.
6. Azhar M, Yin M, Bommireddy R, et al. 2009b. Generation of mice with a conditional allele for transforming growth factor beta 1 gene. Genesis 47: 423-431.
7. Barbara NP, Wrana JL, Letarte M, et al. 1999. Endoglin is an accessory protein that interacts with the signaling receptor complex of multiple members of the transforming growth factor-beta superfamily. J Biol Chem 274: 584-594.
8. Barresi V, Grosso M, Vitarelli E, et al. 2008. Endoglin (CD105) immuno-expression in human foetal and neonatal lungs. Histol Histopathol 23: 701-708.
9. Bartram U, Molin DG, Wisse LJ, et al. 2001. Double-outlet right ventricle and overriding tricuspid valve reflect disturbances of looping, myocardialization, endocardial cushion differentiation, and apoptosis in TGF-beta(2)-knockout mice. Circulation 103: 2745-2752.
10. Beffagna G, Occhi G, Nava A, et al. 2005. Regulatory mutations in transforming growth factor-beta3 gene cause arrhythmogenic right ventricular cardiomyopathy type 1. Cardiovasc Res 65: 366-373.
11. Bharathy S, Xie W, Yingling JM, et al. 2008. Cancer-associated transforming growth factor beta type II receptor gene mutant causes activation of bone morphogenic protein-Smads and invasive phenotype. Cancer Res 68: 1656-1666.
12. Botto LD, May K, Fernhoff PM, et al. 2003. A population-based study of the 22q11.2 deletion: phenotype, incidence, and contribution to major birth defects in the population. Pediatrics 112: 101-107.
13. Bourdeau A, Dumont DJ, Letarte M, et al. 1999. A murine model of hereditary hemorrhagic telangiectasia. J Clin Invest 104: 1343-1351.
14. Boyer AS, Ayerinskas II, Vincent EB, et al. 1999. TGFbeta2 and TGFbeta3 have separate and sequential activities during epithelial-mesenchymal cell transformation in the embryonic heart. Dev Biol 208: 530-545.
15. Brown CB, Boyer AS, Runyan RB, et al. 1999. Requirement of type III TGF-beta receptor for endocardial cell transformation in the heart. Science 283: 2080-2082.
16. Camenisch TD, Molin DG, Person A, et al. 2002. Temporal and distinct TGFbeta ligand requirements during mouse and avian endocardial cushion morphogenesis. Dev Biol 248: 170-181.
17. Carvalho RL, Itoh F, Goumans MJ, et al. 2007. Compensatory signalling induced in the yolk sac vasculature by deletion of TGFbeta receptors in mice. J Cell Sci 120: 4269-4277.
18. Cazac BB, Roes J. 2000. TGF-beta receptor controls B cell responsiveness and induction of IgA in vivo. Immunity 13: 443-451.
19. Choudhary B, Ito Y, Makita T, et al. 2006. Cardiovascular malformations with normal smooth muscle differentiation in neural crest-specific type II TGFbeta receptor (Tgfbr2) mutant mice. Dev Biol 289: 420-429.
20. Choudhary B, Zhou J, Li P, et al. 2009. Absence of TGFbeta signaling in embryonic vascular smooth muscle leads to reduced lysyl oxidase expression, impaired elastogenesis, and aneurysm. Genesis 47: 115-121.
21. Chytil A, Magnuson MA, Wright CV, et al. 2002. Conditional inactivation of the TGF-beta type II receptor using Cre: Lox. Genesis 32: 73-75.
22. Compton LA, Potash DA, Brown CB, et al. 2007. Coronary vessel development is dependent on the type III transforming growth factor beta receptor. Circ Res 101: 784-791.
23. Compton LA, Potash DA, Mundell NA, et al. 2006. Transforming growth factor-beta induces loss of epithelial character and smooth muscle cell differentiation in epicardial cells. Dev Dyn 235: 82-93.
24. David L, Mallet C, Mazerbourg S, et al. 2007. Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells. Blood 109: 1953-1961.
25. Dickson MC, Martin JS, Cousins FM, et al. 1995. Defective haematopoiesis and vasculogenesis in transforming growth factor-beta 1 knock out mice. Development 121: 1845-1854.
26. Diebold RJ, Eis MJ, Yin M, et al. 1995. Early-onset multifocal inflammation in the transforming growth factor beta 1-null mouse is lymphocyte mediated. Proc Natl Acad Sci U S A 92: 12215-12219.
27. Dudas M, Kim J, Li WY, et al. 2006. Epithelial and ectomesenchymal role of the type I TGF-beta receptor ALK5 during facial morphogenesis and palatal fusion. Dev Biol 296: 298-314.
28. Eckman PM, Hsich E, Rodriguez ER, et al. 2009. Impaired systolic function in Loeys-Dietz syndrome: a novel cardiomyopathy? Circ Heart Fail 2: 707-708.
29. Frutkin AD, Shi H, Otsuka G, et al. 2006. A critical developmental role for tgfbr2 in myogenic cell lineages is revealed in mice expressing SM22-Cre, not SMMHC-Cre. Journal of molecular and cellular cardiology 41: 724-731.
30. Gittenberger-de Groot AC, Azhar M, Molin DG, et al. 2006. Transforming growth factor beta-SMAD2 signaling and aortic arch development. Trends Cardiovasc Med 16: 1-6.
31. Gittenberger-de Groot AC, Vrancken Peeters MP, Bergwerff M, et al. 2000. Epicardial outgrowth inhibition leads to compensatory mesothelial outflow tract collar and abnormal cardiac septation and coronary formation. Circ Res 87: 969-971.
32. Gittenberger-de Groot AC, Winter EM, Poelmann RE, et al. 2010. Epicardium-derived cells (EPDCs) in development, cardiac disease and repair of ischemia. J Cell Mol Med 14: 1056-1060.
33. Goumans MJ, Valdimarsdottir G, Itoh S, et al. 2003. Activin receptor-like kinase (ALK)1 is an antagonistic mediator of lateral TGFbeta/ALK5 signaling. Mol Cell 12: 817-828.
34. Goumans MJ, Valdimarsdottir G, Itoh S, et al. 2002. Balancing the activation state of the endothelium via two distinct TGF-beta type I receptors. EMBO J 21: 1743-1753.
35. Hiruma T, Nakajima Y, Nakamura H, et al. 2002. Development of pharyngeal arch arteries in early mouse embryo. J Anat 201: 15-29.
36. Hoffman JI, Kaplan S. 2002. The incidence of congenital heart disease. J Am Coll Cardiol 39: 1890-1900.
37. Holtwick R, Gotthardt M, Skryabin B, et al. 2002. Smooth muscle-selective deletion of guanylyl cyclase-A prevents the acute but not chronic effects of ANP on blood pressure. Proc Natl Acad Sci U S A 99: 7142-7147.
38. Inamoto S, Kwartler CS, Lafont AL, et al. 2010. TGFBR2 mutations alter smooth muscle cell phenotype and predispose to thoracic aortic aneurysms and dissections. Cardiovasc Res 88: 520-529.
39. Jain D, Dietz HC, Oswald GL, et al. 2011. Causes and histopathology of ascending aortic disease in children and young adults. Cardiovasc Pathol 20: 15-25.
40. Jiao K, Langworthy M, Batts L, et al. 2006. Tgfbeta signaling is required for atrioventricular cushion mesenchyme remodeling during in vivo cardiac development. Development 133: 4585-4593.
41. Jones JA, Spinale FG, Ikonomidis JS, et al. 2009. Transforming growth factor-beta signaling in thoracic aortic aneurysm development: a paradox in pathogenesis. J Vascular Res 46: 119-137.
42. Jonker L, Arthur HM. 2002. Endoglin expression in early development is associated with vasculogenesis and angiogenesis. Mech Dev 110(1-2): 193-196.
43. Kaartinen V, Voncken JW, Shuler C, et al. 1995. Abnormal lung development and cleft palate in mice lacking TGF-beta 3 indicates defects of epithelial-mesenchymal interaction. Nat Genet 11: 415-421.
44. Kirby ML. 2007. Cardiac Development. New York: Oxford University Press.
45. Kirkbride KC, Townsend TA, Bruinsma MW, et al. 2008. Bone morphogenetic proteins signal through the transforming growth factor-beta type III receptor. J Biol Chem 283: 7628-7637.
46. Kisanuki YY, Hammer RE, Miyazaki J, et al. 2001. Tie2-Cre transgenic mice: a new model for endothelial cell-lineage analysis in vivo. Dev Biol 230: 230-242.
47. Kulkarni AB, Huh CG, Becker D, et al. 1993. Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci U S A 90: 770-774.
48. Langlois D, Hneino M, Bouazza L, et al. 2010. Conditional inactivation of TGF-beta type II receptor in smooth muscle cells and epicardium causes lethal aortic and cardiac defects. Transgenic Res 19: 1069-1082.
49. Larsson J, Goumans MJ, Sjostrand LJ, et al. 2001. Abnormal angiogenesis but intact hematopoietic potential in TGF-beta type I receptor-deficient mice. EMBO J 20: 1663-1673.
50. Lawler S, Candia AF, Ebner R, et al. 1994. The murine type II TGF-beta receptor has a coincident embryonic expression and binding preference for TGF-beta 1. Development 120: 165-175.
51. Lebrin F, Goumans MJ, Jonker L, et al. 2004. Endoglin promotes endothelial cell proliferation and TGF-beta/ALK1 signal transduction. EMBO J 23: 4018-4028.
52. Letterio JJ, Geiser AG, Kulkarni AB, et al. 1994. Maternal rescue of transforming growth factor-beta 1 null mice. Science 264: 1936-1938.
53. Leveen P, Larsson J, Ehinger M, et al. 2002. Induced disruption of the transforming growth factor beta type II receptor gene in mice causes a lethal inflammatory disorder that is transplantable. Blood 100: 560-568.
54. Li DY, Sorensen LK, Brooke BS, et al. 1999. Defective angiogenesis in mice lacking endoglin. Science 284: 1534-1537.
55. Li P, Pashmforoush M, Sucov HM, et al. 2010. Retinoic acid regulates differentiation of the secondary heart field and TGFbeta-mediated outflow tract septation. Dev Cell 18: 480-485.
56. Lin F, Yang X. 2010. TGF-beta signaling in aortic aneurysm: another round of controversy. J Genet Genomics 37: 583-591.
57. Loeys BL, Schwarze U, Holm T, et al. 2006. Aneurysm syndromes caused by mutations in the TGF-beta receptor. N Engl J Med 355: 788-798.
58. Lopez-Novoa JM, Bernabeu C. 2010. The physiological role of endoglin in the cardiovascular system. Am J Physiol 299: H959-974.
59. Mahmoud M, Allinson KR, Zhai Z, et al. 2010. Pathogenesis of arteriovenous malformations in the absence of endoglin. Circ Res 106: 1425-1433.
60. Mancini ML, Verdi JM, Conley BA, et al. 2007. Endoglin is required for myogenic differentiation potential of neural crest stem cells. Dev Biol 308: 520-533.
61. Mariano JM, Montuenga LM, Prentice MA, et al. 1998. Concurrent and distinct transcription and translation of transforming growth factor-beta type I and type II receptors in rodent embryogenesis. Int J Dev Biol 42: 1125-1136.
62. Markowitz S, Wang J, Myeroff L, et al. 1995. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science 268: 1336-1338.
63. Mercado-Pimentel ME, Hubbard AD, Runyan RB, et al. 2007. Endoglin and Alk5 regulate epithelial-mesenchymal transformation during cardiac valve formation. Dev Biol 304: 420-432.
64. Moessler H, Mericskay M, Li Z, Nagl S, Paulin D, Small JV. 1996. The SM 22 promoter directs tissue-specific expression in arterial but not in venous or visceral smooth muscle cells in transgenic mice. Development 122: 2415-2425.
65. Molin DG, Bartram U, Van Der Heiden K, et al. 2003. Expression patterns of Tgfbeta1-3 associate with myocardialisation of the outflow tract and the development of the epicardium and the fibrous heart skeleton. Dev Dyn 227: 431-444.
66. Molin DG, DeRuiter MC, Wisse LJ, et al. 2002. Altered apoptosis pattern during pharyngeal arch artery remodelling is associated with aortic arch malformations in Tgfbeta2 knock-out mice. Cardiovasc Res 56: 312-322.
67. Molin DG, Poelmann RE, DeRuiter MC, et al. 2004. Transforming growth factor beta-SMAD2 signaling regulates aortic arch innervation and development. Circ Res 95: 1109-1117.
68. Moore AW, McInnes L, Kreidberg J, et al. 1999. YAC complementation shows a requirement for Wt1 in the development of epicardium, adrenal gland and throughout nephrogenesis. Development 126: 1845-1857.
69. Mu Z, Yang Z, Yu D, et al. 2008. TGFbeta1 and TGFbeta3 are partially redundant effectors in brain vascular morphogenesis. Mech Dev 125: 508-516.
70. Mummery CL. 2001. Transforming growth factor beta and mouse development. Microsc Res Tech 52: 374-386.
71. Neptune ER, Frischmeyer PA, Arking DE, et al. 2003. Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome. Nat Genet 33: 407-411.
72. Nomura-Kitabayashi A, Anderson GA, Sleep G, et al. 2009. Endoglin is dispensable for angiogenesis, but required for endocardial cushion formation in the midgestation mouse embryo. Dev Biol 335: 66-77.
73. Oshima M, Oshima H, Taketo MM, et al. 1996. TGF-beta receptor type II deficiency results in defects of yolk sac hematopoiesis and vasculogenesis. Dev Biol 179: 297-302.
74. Pardali E, Goumans MJ, ten Dijke P. 2010. Signaling by members of the TGF-beta family in vascular morphogenesis and disease. Trends Cell Biol 20: 556-567.
75. Park SO, Wankhede M, Lee YJ, et al. 2009. Real-time imaging of de novo arteriovenous malformation in a mouse model of hereditary hemorrhagic telangiectasia. J Clin Invest 119: 3487-3496.
76. Potts JD, Runyan RB. 1989. Epithelial-mesenchymal cell transformation in the embryonic heart can be mediated, in part, by transforming growth factor beta. Dev Biol 134: 392-401.
77. Proetzel G, Pawlowski SA, Wiles MV, et al. 1995. Transforming growth factor-beta 3 is required for secondary palate fusion. Nat Genet 11: 409-414.
78. Qu R, Silver MM, Letarte M, et al. 1998. Distribution of endoglin in early human development reveals high levels on endocardial cushion tissue mesenchyme during valve formation. Cell Tissue Res 292: 333-343.
79. Red-Horse K, Ueno H, Weissman IL, et al. 2010. Coronary arteries form by developmental reprogramming of venous cells. Nature 464: 549-553.
80. Robson A, Allinson KR, Anderson RH, et al. 2010. The TGFbeta type II receptor plays a critical role in the endothelial cells during cardiac development. Dev Dyn 239: 2435-2442.
81. Roelen BA, Lin HY, Knezevic V, et al. 1994. Expression of TGF-betas and their receptors during implantation and organogenesis of the mouse embryo. Dev Biol 166: 716-728.
82. Rosenkranz S. 2004. TGF-beta1 and angiotensin networking in cardiac remodeling. Cardiovasc Res 63: 423-432.
83. Sanford LP, Ormsby I, Gittenberger-de Groot AC, et al. 1997. TGFbeta2 knockout mice have multiple developmental defects that are non-overlapping with other TGFbeta knockout phenotypes. Development 124: 2659-2670.
84. Sankar S, Mahooti-Brooks N, Centrella M, et al. 1995. Expression of transforming growth factor type III receptor in vascular endothelial cells increases their responsiveness to transforming growth factor beta 2. J Biol Chem 270: 13567-13572.
85. Seki T, Hong KH, Oh SP, et al. 2006. Nonoverlapping expression patterns of ALK1 and ALK5 reveal distinct roles of each receptor in vascular development. Lab Invest 86: 116-129.
86. Shovlin CL. 2010. Hereditary haemorrhagic telangiectasia: pathophysiology, diagnosis and treatment. Blood Rev 24: 203-219.
87. Shull MM, Ormsby I, Kier AB, et al. 1992. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature 359: 693-699.
88. Sorensen LK, Brooke BS, Li DY, et al. 2003. Loss of distinct arterial and venous boundaries in mice lacking endoglin, a vascular-specific TGFbeta coreceptor. Dev Biol 261: 235-250.
89. Sridurongrit S, Larsson J, Schwartz R, et al. 2008. Signaling via the Tgf-beta type I receptor Alk5 in heart development. Dev Biol 322: 208-218.
90. Stenvers KL, Tursky ML, Harder KW, et al. 2003. Heart and liver defects and reduced transforming growth factor beta2 sensitivity in transforming growth factor beta type III receptor-deficient embryos. Mol Cell Biol 23: 4371-4385.
91. Tang Y, Lee KS, Yang H, et al. 2005. Epistatic interactions between modifier genes confer strain-specific redundancy for Tgfb1 in developmental angiogenesis. Genomics 85: 60-70.
92. Tang Y, McKinnon ML, Leong LM, et al. 2003. Genetic modifiers interact with maternal determinants in vascular development of Tgfb1(-/-) mice. Hum Mol Genet 12: 1579-1589.
93. ten Dijke P, Arthur HM. 2007. Extracellular control of TGFbeta signalling in vascular development and disease. Nat Rev Mol Cell Biol 8: 857-869.
94. Todorovic V, Frendewey D, Gutstein DE, et al. 2007. Long form of latent TGF-beta binding protein 1 (Ltbp1L) is essential for cardiac outflow tract septation and remodeling. Development 134: 3723-3732.
95. Tomanek RJ. 2005. Formation of the coronary vasculature during development. Angiogenesis 8: 273-284.
96. Upton PD, Davies RJ, Trembath RC, et al. 2009. Bone morphogenetic protein (BMP) and activin type II receptors balance BMP9 signals mediated by activin receptor-like kinase-1 in human pulmonary artery endothelial cells. J Biol Chem 284: 15794-15804.
97. Van Hemelrijk C, Renard M, Loeys B, et al. 2010. The Loeys-Dietz syndrome: an update for the clinician. Curr Opin Cardiol 25: 546-551.
98. Wang J, Nagy A, Larsson J, et al. 2006. Defective ALK5 signaling in the neural crest leads to increased postmigratory neural crest cell apoptosis and severe outflow tract defects. BMC Dev Biol 6: 51.
99. Wang YQ, Sizeland A, Wang XF, et al. 1995. Restricted expression of type-II TGF beta receptor in murine embryonic development suggests a central role in tissue modeling and CNS patterning. Mech Dev 52: 275-289.
100. Wu MY, Hill CS. 2009. Tgf-beta superfamily signaling in embryonic development and homeostasis. Dev Cell 16: 329-343.
101. Wurdak H, Ittner LM, Lang KS, et al. 2005. Inactivation of TGFbeta signaling in neural crest stem cells leads to multiple defects reminiscent of DiGeorge syndrome. Genes Dev 19: 530-535.
102. Xiao H, Zhang YY. 2008. Understanding the role of transforming growth factor-beta signalling in the heart: overview of studies using genetic mouse models. Clin Exp Pharmacol Physiol 35: 335-341.
103. Yashiro K, Shiratori H, Hamada H, et al. 2007. Haemodynamics determined by a genetic programme govern asymmetric development of the aortic arch. Nature 450: 285-288.
104. Zhang YE. 2009. Non-Smad pathways in TGF-beta signaling. Cell Res 19: 128-139.
105. Zhao H, Oka K, Bringas P, et al. 2008. TGF-beta type I receptor Alk5 regulates tooth initiation and mandible patterning in a type II receptor-independent manner. Dev Biol 320: 19-29.